Charles Landis

6.2k total citations · 2 hit papers
62 papers, 2.4k citations indexed

About

Charles Landis is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Charles Landis has authored 62 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hepatology, 35 papers in Epidemiology and 16 papers in Surgery. Recurrent topics in Charles Landis's work include Hepatitis C virus research (30 papers), Liver Disease Diagnosis and Treatment (27 papers) and Liver Disease and Transplantation (17 papers). Charles Landis is often cited by papers focused on Hepatitis C virus research (30 papers), Liver Disease Diagnosis and Treatment (27 papers) and Liver Disease and Transplantation (17 papers). Charles Landis collaborates with scholars based in United States, Canada and Japan. Charles Landis's co-authors include Fred Poordad, Frank Telang, Charles S. Springer, Xin Li, Eugene R. Schiff, Eugene Swenson, Stephanie Noviello, John M. Vierling, Rong Yang and Eric Hughes and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Charles Landis

60 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

2016 331 citations Eugene R. Schiff, John M. Vierling et al. Hepatology profile →
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

2019 205 citations Michael Trauner, Aliya Gulamhusein et al. Hepatology profile →

Peers

Charles Landis

HEPAT

EPIDE

SURGE

RNMI

Gary P. Jeffrey Australia

Heather Patton United States

E B Keeffe United States

Sumihito Tamura Japan

Walid S. Ayoub United States

Manuel Rodríguez‐Perálvarez Spain

Mylène Sebagh France

Nicole E. Rich United States

Jean‐Didier Grangé France

Arndt Weinmann Germany

Gary P. Jeffrey Australia

Charles Landis

2.3k ×1.5

HEPAT

2.5k ×2.0

EPIDE

638 ×1.3

SURGE

182 ×0.5

RNMI

135 ×0.5

Citations per year, relative to Charles Landis Charles Landis (= 1×) peers Gary P. Jeffrey

Countries citing papers authored by Charles Landis

Since Specialization

Citations

This map shows the geographic impact of Charles Landis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Landis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Landis more than expected).

Fields of papers citing papers by Charles Landis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Landis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Landis. The network helps show where Charles Landis may publish in the future.

Co-authorship network of co-authors of Charles Landis

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Landis. A scholar is included among the top collaborators of Charles Landis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Landis. Charles Landis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Royo, C., et al.. (2025). Low-level direct currents eradicate multi-drug-resistant Candidozyma auris through physiological stress and antifungal permeation. Chemical Engineering Journal. 520. 166070–166070. 1 indexed citations

Kim, Nicole J., Amy M. Shui, Michele Tana, et al.. (2023). Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals. JAMA Network Open. 6(6). e2317549–e2317549. 14 indexed citations

Bender, Andrew T., Lorraine Lillis, Wynn Burke, et al.. (2022). Rapid detection of hepatitis C virus using recombinase polymerase amplification. PLoS ONE. 17(10). e0276582–e0276582. 10 indexed citations

Trauner, Michael, Christopher L. Bowlus, Aliya Gulamhusein, et al.. (2022). Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC. Clinical Gastroenterology and Hepatology. 21(6). 1552–1560.e2. 28 indexed citations

Yeh, Ming‐Lun, Pei‐Chien Tsai, Shu‐Chi Wang, et al.. (2021). Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. Cancers. 13(14). 3455–3455. 12 indexed citations

Verna, Elizabeth C., Giuseppe Morelli, Norah A. Terrault, et al.. (2020). DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. Journal of Hepatology. 73(3). 540–548. 81 indexed citations

Lawitz, Eric, Charles Landis, Steven L. Flamm, et al.. (2020). Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. The Lancet. Gastroenterology & hepatology. 5(10). 918–926. 21 indexed citations

Trauner, Michael, Aliya Gulamhusein, Bilal Hameed, et al.. (2019). The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.. Hepatology. 3 indexed citations

Bourlière, Marc, Stuart C. Gordon, Eugene R. Schiff, et al.. (2018). Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. The Lancet. Gastroenterology & hepatology. 3(8). 559–565. 18 indexed citations

10.

Hirschfield, Gideon M., Olivier Chazouillères, Joost P.H. Drenth, et al.. (2018). Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. Journal of Hepatology. 70(3). 483–493. 147 indexed citations

11.

Lim, Joseph K., Mitchell L. Shiffman, Anna S. Lok, et al.. (2018). Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology. 16(11). 1811–1819.e4. 13 indexed citations

12.

Choi, Won‐Tak, Keith R. Jerome, Linda Cook, et al.. (2017). Biopsy Specimens From Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection After Virus Eradication. Clinical Gastroenterology and Hepatology. 15(8). 1279–1285. 22 indexed citations

13.

Lawitz, Eric, Charles Landis, Benedict Maliakkal, et al.. (2017). Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment.. 66. 13 indexed citations

14.

Landis, Charles, Marwan Ghabril, Vinod K. Rustgi, et al.. (2016). Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy. Digestive Diseases and Sciences. 61(6). 1728–1734. 10 indexed citations

15.

Su, Feng, Lei Yu, Kristin Berry, et al.. (2015). Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. Gastroenterology. 150(2). 441–453.e6. 142 indexed citations

16.

Rayhill, Stephen C., et al.. (2015). Liver Transplantation for Urea Cycle Disorders: Analysis of the United Network for Organ Sharing Database. Transplantation Proceedings. 47(8). 2413–2418. 29 indexed citations

17.

Kuwahara, Reiichiro, Alexander Kofman, Charles Landis, et al.. (2008). The hepatic stem cell niche: Identification by label-retaining cell assay. Hepatology. 47(6). 1994–2002. 188 indexed citations

18.

Landis, Charles, Kosho Yamanouchi, Hongchao Zhou, et al.. (2006). Noninvasive evaluation of liver repopulation by transplanted hepatocytes using 31P MRS imaging in mice. Hepatology. 44(5). 1250–1258. 21 indexed citations

19.

Landis, Charles, et al.. (1999). Equilibrium transcytolemmal water-exchange kinetics in skeletal muscle in vivo. Magnetic Resonance in Medicine. 42(3). 467–478. 181 indexed citations

20.

Landis, Charles, Xin Li, Frank Telang, et al.. (1999). Equilibrium transcytolemmal water‐exchange kinetics in skeletal muscle in vivo. Magnetic Resonance in Medicine. 42(3). 467–478. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact